Related Experiment Video
Updated: Mar 12, 2026
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
The sL1CAM in sera of patients with endometrial and ovarian cancers
Michał Wojciechowski1,2, Ewa Głowacka3, Miłosz Wilczyński4
1Department of Surgical, Endoscopic Gynecology and Oncology, Polish Mother's Memorial Hospital-Research Institute, 281/283 Rzgowska St., 93-338, Łódź, Poland. wojmich@gmail.com.
Purpose:
L1CAM is a cell adhesion molecule suspected to play an important role in carcinogenesis. The objective of the study was to evaluate the level of soluble L1CAM in the sera of patients with endometrial and ovarian carcinomas and verify the feasibility of the sL1CAM as a marker of these carcinomas.
Methods:
35 endometrial and 18 ovarian cancer patients were enrolled in the study. 43 patients with benign gynecological conditions constituted a control group. The sL1CAM serum level was measured with ELISA test in each patient and it was referred to the data from the surgical staging of the cancers.
Results:
The sL1CAM serum level was significantly lower in patients with endometrial cancer than in healthy women and slightly lower in the ovarian cancer group than in the control group. In the endometrial cancer group there was no correlation between sL1CAM concentration and cancer histopathology, stage or grade. sL1CAM concentration positively correlated with ovarian cancer stage and (not significantly) with grade.
Conclusions:
Despite the increasing data about the possible role of L1CAM as a strong prognostic factor of poor outcome in many cancers, we did not find evidence supporting the use of sL1CAM as a marker of endometrial or ovarian cancers.
